Request To Download Free Sample of This Strategic Report @ Introduction: The Vietnam protein therapeutics market is witnessing significant growth driven by factors such as increasing prevalence of ...

The antibodies target a stable part of the bird flu virus, ensuring that the immune protection can resist new variants and ...

The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, ...

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old.The virus-like particle (VLP) single-dose chikungunya ...

Scientists found that a moderate dose of MEDI8852, an antibody therapy, effectively protected monkeys against severe H5N1 avian flu.

Chugai Pharm signs collaboration agreement with GSK's Global Health Unit for development of anti-dengue virus antibody: Tokyo Friday, January 31, 2025, 09:00 Hrs [IST] Chugai Phar ...

A prophylactic antibody-based immune therapy protects monkeys against severe disease caused by H5N1 avian flu, University of Pittsburgh and NIH Vaccine Research Center researchers report today in ...

A prophylactic antibody-based immune therapy has been shown to protect monkeys against severe bird flu caused by H1N1.

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission has asked the Committee for Medicinal Products for Human Use (CHMP) to consider two ...